Imvelaphi

I-Thalidomide yaziswa njengechiza lokuthomalalisa, i-immunomodulatory agent kwaye iphandwa ukunyanga iimpawu zomhlaza ezininzi.,eyi-CRBN-DDB1-Cul4A complex.

Inkcazo

I-Thalidomide ikhuthazwa ekuqaleni njenge-sedative, inhibits cereblon (CRBN), inxalenye ye-cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, kunye ne-Kd∼250 nM, kwaye ine-immunomodulatory, anti-inflammatory kunye ne-anti-angiogenic cancer cancer properties.

I-In vitro

I-Thalidomide ikhuthazwa ekuqaleni njenge-sedative, ine-immunomodulatory, i-anti-inflammatory kunye ne-anti-angiogenic properties, kwaye ijolise kwi-cereblon (CRBN), inxalenye ye-cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, kunye ne-Kd∼250 nM[1]. IThalidomide (50μi-g / mL) ibangela umsebenzi wokulwa ne-tumor we-icotinib ngokuchasene nokunyuka kwe-PC9 kunye neeseli ze-A549, kwaye esi siphumo sihambelana ne-apoptosis kunye nokufuduka kweeseli. Ukongezelela, i-Thalidomide kunye ne-icotinib inqanda i-EGFR kunye ne-VEGF-R2 iindlela kwiiseli ze-PC9 [3].

I-Thalidomide (i-100 mg / kg, i-po) inqanda ukufakwa kwe-collagen, phantsi-ilawula inqanaba lokubonisa i-mRNAα-SMA kunye ne-collagen I, kwaye iyanciphisa kakhulu i-cytokines e-pro-inflammatory kwiigundane ze-RILF. I-Thalidomide inciphisa i-RILF ngokucinezela i-ROS kunye nolawulo oluphantsi lwe-TGF-β/Indlela yeSmad ixhomekeke kwisimo se-Nrf2[2]. I-Thalidomide (200 mg/kg, po) idityaniswe ne-icotinib ibonisa iziphumo ze-synergistic anti-tumor kwiimpuku ezihamba ze ezithwele iiseli ze-PC9, ukucinezela ukukhula kwethumba kunye nokukhuthaza ukufa kwethumba[3].